Tom Hudson, AbbVie SVP of R&D and CSO
AbbVie discards PhIIb autoimmune drug from 10-year-old discovery pact, citing chronic toxicology study
When Abbott spun out its R&D group into AbbVie back in 2013, it also handed off a drug discovery deal that it had struck just …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
